Connecticut Wealth Management’s Halozyme HALO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$365K Hold
4,668
0.01% 272
2026
Q1
$302K Hold
4,668
0.01% 279
2025
Q4
$314K Sell
4,668
-280
-6% -$18.8K 0.01% 262
2025
Q3
$363K Sell
4,948
-486
-9% -$32.3K 0.02% 255
2025
Q2
$283K Sell
5,434
-158
-3% -$8.99K 0.01% 264
2025
Q1
$357K Buy
5,592
+16
+0.3% +$929 0.02% 240
2024
Q4
$267K Buy
5,576
+31
+0.6% +$1.59K 0.01% 236
2024
Q3
$317K Sell
5,545
-530
-9% -$30.4K 0.02% 260
2024
Q2
$318K Buy
6,075
+200
+3% +$8.77K 0.02% 257
2024
Q1
$239K Buy
5,875
+68
+1% +$2.55K 0.01% 297
2023
Q4
$215K Hold
5,807
0.01% 305
2023
Q3
$222K Hold
5,807
0.02% 273
2023
Q2
$209K Buy
+5,807
New +$198K 0.01% 253

Other funds holding HALO

Connecticut Wealth Management's HALO Position: Q2 2026 in Review

Connecticut Wealth Management held its Halozyme (HALO) position steady in Q2 2026 at 4,668 shares worth $365K. The position accounts for 0.01% of the portfolio, ranked #272.

Connecticut Wealth Management first reported a position in HALO in Q2 2023 and has held it in 13 quarters since. 289 funds tracked by Wall St. Rank hold HALO as of Q2 2026.

  • Connecticut Wealth Management held 4,668 shares of Halozyme worth $365K as of Q2 2026.
  • Connecticut Wealth Management left its Halozyme share count unchanged in Q2 2026.
  • Halozyme made up 0.01% of Connecticut Wealth Management's portfolio in Q2 2026, its #272 holding.
  • Connecticut Wealth Management first reported a position in Halozyme in Q2 2023 and has held it in 13 quarters since.
  • 289 funds tracked by Wall St. Rank held Halozyme as of Q2 2026.

Based on Connecticut Wealth Management's 13F filing for Q2 2026, filed 29 Jul 2026.